Safety and Efficacy Study of BDB-001 Injection in Patients With Moderate to Severe Hidradenitis Suppurativa (HS)

Exclusion Criteria

• •Subject was previously treated with adalimumab or another biologic product during the 3 months before the first administration;
• •Subject received any oral antibiotic treatment for HS within 2 weeks before the first administration;
• •Subject received any oral retinoids treatment for HS within 4 weeks before the first administration;
• •Subject received oral opioids analgesics within 1 week before the first administration;
• •Systematic treatment with glucocorticoid or intramural injection within 4 weeks before the first administration;
• •History of heart disease or malignancy.